MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.

By whole-genome and/or Sanger sequencing, we recently identified a somatic mutation (MYD88 L265P) that stimulates nuclear factor κB activity and is present in >90% of Waldenström macroglobulinemia (WM) patients. MYD88 L265P was absent in 90% of immunoglobulin M (IgM) monoclonal gammopathy of undetermined significance (MGUS) patients. We therefore developed conventional and real-time allele-specific polymerase chain reaction (AS-PCR) assays for more sensitive detection and quantification of MYD88 L265P. Using either assay, MYD88 L265P was detected in 97 of 104 (93%) WM and 13 of 24 (54%) IgM MGUS patients and was either absent or rarely expressed in samples from splenic marginal zone lymphoma (2/20; 10%), CLL (1/26; 4%), multiple myeloma (including IgM cases, 0/14), and immunoglobulin G MGUS (0/9) patients as well as healthy donors (0/40; P < 1.5 × 10(-5) for WM vs other cohorts). Real-time AS-PCR identified IgM MGUS patients progressing to WM and showed a high rate of concordance between MYD88 L265P ΔCT and BM disease involvement (r = 0.89, P = .008) in WM patients undergoing treatment. These studies identify MYD88 L265P as a widely present mutation in WM and IgM MGUS patients using highly sensitive and specific AS-PCR assays with potential use in diagnostic discrimination and/or response assessment. The finding of this mutation in many IgM MGUS patients suggests that MYD88 L265P may be an early oncogenic event in WM pathogenesis.

[1]  J. Cerhan,et al.  MYD88 Pathway Activation in Lymphoplasmacytic Lymphoma Drives Tumor Cell Growth and Cytokine Expression. , 2012 .

[2]  M. Cazzola,et al.  Prevalence and Clinical Significance of the MYD88 (L265P) Somatic Mutation in Patients with Waldenström Macroglobulinemia, IgM-Monoclonal Gammopathy of Undetermined Significance or Other Mature B-Cell Neoplasms. , 2012 .

[3]  N. Harris,et al.  MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. , 2012, The New England journal of medicine.

[4]  S. Treon,et al.  Use of whole genome sequencing to identify highly recurrent somatic mutations in Waldenström’s macroglobulinemia. , 2012 .

[5]  S. Treon,et al.  Participation of BTK in MYD88 signaling in malignant cells expressing the L265P mutation in Waldenstrom’s macroglobulinemia, and effect on tumor cells with BTK-inhibitor PCI-32765 in combination with MYD88 pathway inhibitors. , 2012 .

[6]  S. Treon,et al.  Disruption of MYD88 Pathway Signaling Leads to Loss of Constitutive IRAK1, NF-κβ and JAK/STAT Signaling and Induces Apoptosis of Cells Expressing the MYD88 L265P Mutation in Waldenstrom's Macroglobulinemia , 2011 .

[7]  R. Siebert,et al.  Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma , 2011, Acta Neuropathologica.

[8]  Raul Rabadan,et al.  Analysis of the Coding Genome of Diffuse Large B-Cell Lymphoma , 2011, Nature Genetics.

[9]  Juliane C. Dohm,et al.  Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia , 2011, Nature.

[10]  Hsiuyi Tseng,et al.  Attainment of complete/very good partial response following rituximab‐based therapy is an important determinant to progression‐free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia , 2011, British journal of haematology.

[11]  R. Fonseca,et al.  Establishment and characterization of a novel Waldenstrom macroglobulinemia cell line, MWCL-1. , 2011, Blood.

[12]  Joseph M. Connors,et al.  Oncogenically active MYD88 mutations in human lymphoma , 2011, Nature.

[13]  Y. Lo,et al.  Helical assembly in the MyD88:IRAK4:IRAK2 complex in TLR/IL-1R signaling , 2010, Nature.

[14]  C. Sette,et al.  Identification of Critical Residues of the MyD88 Death Domain Involved in the Recruitment of Downstream Kinases* , 2009, Journal of Biological Chemistry.

[15]  C. Pascutto,et al.  Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Osamu Takeuchi,et al.  Sequential control of Toll-like receptor–dependent responses by IRAK1 and IRAK2 , 2008, Nature Immunology.

[17]  D. Carrasco,et al.  Targeting NF-kappaB in Waldenstrom macroglobulinemia. , 2008, Blood.

[18]  J. Briones,et al.  High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma , 2008, Haematologica.

[19]  J. Kutok,et al.  Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. , 2007, Experimental hematology.

[20]  L. O'Neill,et al.  Structure, function and regulation of the Toll/IL‐1 receptor adaptor proteins , 2007, Immunology and cell biology.

[21]  A. Rossi,et al.  Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  R. Foà,et al.  Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma. , 2005, Blood.

[23]  L. Cavanna,et al.  Clinical characteristics and factors predicting evolution of asymptomatic IgM monoclonal gammopathies and IgM-related disorders , 2004, Leukemia.

[24]  M Hummel,et al.  Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936 , 2003, Leukemia.

[25]  T. Therneau,et al.  Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. , 2003, Seminars in oncology.

[26]  M. Dimopoulos,et al.  Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. , 2003, Seminars in oncology.

[27]  P. Baeuerle,et al.  IKAP is a scaffold protein of the IκB kinase complex , 1998, Nature.

[28]  I. Soubeyran,et al.  IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas , 2013, Leukemia.

[29]  L Cohen,et al.  IKAP is a scaffold protein of the IkappaB kinase complex. , 1998, Nature.

[30]  Melinda Fitzgerald,et al.  Immunol. Cell Biol. , 1995 .